Long-term treatment of schizophrenia: Moving from a relapse prevention model to a recovery model

Advanced Studies in Medicine

Volumn 3, Issue 8 C, 2003, Pages

  Kane, John M ^a,b,c  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE;

BEHAVIOR THERAPY; COGNITIVE THERAPY; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; OUTCOMES RESEARCH; PSYCHOSOCIAL CARE; RECURRENCE RISK; RELAPSE; REMISSION; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL SUPPORT; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 0242526714     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156(4):544-549.
2. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247.
3. Liberman RP, Kopelowicz A. Recovery from schizophrenia: a challenge for the 21 st century. Int Rev Psychiatry. 2002;14:256-272.
4. Kane JM. Schizophrenia. N Engl J Med. 1996;334(1): 34-41.
5. Schooler NR, Keith SJ, Severe JB, Mathews SM. Treatment strategies in schizophrenia: effects of dosage reduction and family management outcome. Schizophr Res. 1993;9:260.
6. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry. 1990;147:1138-1148.
7. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry. 1991;48:333-339.
8. Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ. 1989;298:985-990.
9. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ. 1990;301:837-842.
10. Pietzcker A, Gaebel W, Köpcke W, et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenio: 2-year results of a German multicenter study. J Psychiatr Res. 1993;27:321-339.
11. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40.
12. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825-835.
13. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111-123.
14. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42(4):233-246.
15. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796.
16. Kane J, Carson W, Kujawa M, et al. Aripiprazole vs perphenazine in treatment-resistant schizophrenia. Poster presented at the 2003 American Psychiatric Association Annual Meeting; May 17-22, 2003; San Francisco, California.
17. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209-1222.
18. Kujawa M, Saha A, Ingenito G, et al. Aripiprazole for long-term maintenance treatment of schizophrenia [abstract]. Int J Neuropsychopharmacol. 2002;5(suppl 1):S186.